Opioid Use Disorder
Primary care office-based addiction treatment of opioid use disorder with buprenorphine is a realistic and scalable solution to address the overdose crisis in the United States.
Stigmatizing terms used to describe individuals who have a substance addiction, including "addict," alcoholic," and "substance abuser," may be associated with negative explicit and implicit biases and should be replaced with positive terms that still describe the conditions accurately.
Pending approval, CAM2038 may be the first long-acting treatment for OUD in both weekly and monthly formulations.
American emergency medicine physicians have been taking measures to address the ongoing opioid crisis, which affects emergency departments throughout the country.
Few of the individuals who experience an opioid-related overdose had received treatment for opioid use disorder.
Mental health, education level, and recent drug use may be associated with duration of treatment with extended-release naltrexone for opioid dependence.
Based on current evidence, there is a strong consensus that medication-assisted treatment is recommended over detoxification in the treatment of opioid use disorder during pregnancy.
A longer duration of extended-release naltrexone treatment in individuals with opioid dependence was associated with improved outcomes and reduced rates of relapse.
According to the authors, this report represents the first case of recurrent fallacious lactatemia secondary to EG poisoning in the setting of drug-seeking behavior.
National Institutes of Health Director, Francis Collins, MD, PhD, announced on April 4, 2018 the launch of the Helping to End Addiction Long-Term Initiative.
Adolescents with anxiety, mood, neurodevelopmental, sleep, and nonopioid substance use disorders and most mental health treatments were significantly more likely to receive opioids.
A new guideline recommends opioid agonist therapy with buprenorphine-naloxone as first-line for the treatment of opioid use disorder.
Various strategies to reduce opioid overdose deaths have been implemented and it has been suggested that access to medical cannabis may lead to a reduction in opioid use for pain management.
Extended-release naltrexone and sublingual buprenorphine-naloxone were equally effective for preventing opioid abuse relapse.
Slow-Release Oral Morphine, a Promising Opioid Agonist Therapy Alternative to Buprenorphine, MethadoneJanuary 11, 2018
Slow-release oral morphine may be a valuable tool to help reduce the number of deaths from opioid-related overdose.
New guidelines were formulated for the use of urine drug monitoring in risk stratification and the prevention of opioid use disorder, overdose, and diversion.
In a press release issued November 30, 2017, the US Food and Drug Administration announced it has approved Sublocade, a once-monthly buprenorphine injection for moderate to severe opioid use disorder.
Immediate access to opioid agonist treatment for patients presenting with opioid use disorder may provide greater health benefits at less cost than observed standard of care.
A motivational interviewing intervention delivered by trained counselors reduced the rate of opioid overdoses in participants with opioid use disorder.
Patients with opioid and/or alcohol use disorders have better treatment access and greater rates of alcohol and drug abstinence at 6 months with collaborative care vs standard addiction care.
The extended-release formulation of tramadol was shown to be as effective as buprenorphine and more effective than clonidine for treating symptoms of opioid withdrawal.
Once-weekly subcutaneous buprenorphine injections block the euphoric effects of opioids and suppress opioid withdrawal in patients with opioid use disorder.
Early pharmacologic intervention for opioid use disorder after diagnosis is crucial to prevent relapse and overdose in adolescents and young adults.
Discrepancies in Subjective vs Objective Sleep in Patients Receiving Buprenorphine for Opioid Use DisorderJune 20, 2017
Patients receiving buprenorphine maintenance therapy for their opioid use disorder may have impaired sleep, despite their reports of improved quality and duration of sleep.
A recent study found high rates of mortality and morbidity in patients with opioid use disorder in a large healthcare system.
The researchers found that novice prescribers cited insufficient access to substance abuse counseling for patients, as well as insufficient access to more experienced prescribers, as reasons for not treating more patients.
A small fraction of prescriptions for Medicare patients are for opioid agonist therapy, despite higher rates of abuse.
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- FDA Approves Minimally-Invasive, Non-Drug Therapy for Pain Management
- Chronic Migraine and Medication Overuse Headache Linked to Stress
- Set of Personality Traits May Predict Prescription Drug Use, Misuse in Young Adults
- The Opioid Crisis: District by District
- Opioid Administration, Prescribing in the ED on the Decline in Recent Years